Prevention and treatment of early postoperative deep vein thrombosis in africans: a Nigerian experience with dihydroergotamine mesylate.
Post-operative deep vein thrombosis is regarded as rare among Africans, even though there are no known specific factors existing in the African population which either increase or decrease the incidence of deep vein thrombosis in the surgical patient. But by using human fibrinogen labeled with radioactive iodine (125I), despite its limitations in detecting thrombi proximal to the femoral veins, we were able to demonstrate those which were still at the subclinical stage of the disease process apart from overt cases of deep vein thrombosis (DVT). Whereas, miniheparinization and treatment with Dextran 70 may be better, accepted methods of prophylaxis in the immediate post-operative days, in 38 consecutive post-operative cases studied, we were able to show the benefits of dihydroergotamine mesylate in the prevention of deep vein thrombosis among Nigerians. It was also shown that since DVT may occur in the femoral segments without a concomitant involvement of the calf veins, assertions based only on data obtained from clinical examinations of the calf for evidence of DVT are bound to be understatements of the true incidence.
D000328:Adult; D000368:Aged; D004087:Dihydroergotamine / Q000627:therapeutic use*; D005260:Female; D005340:Fibrinogen; D006801:Humans; D008297:Male; D008875:Middle Aged; D009549:Nigeria; D011183:Postoperative Complications / Q000188:drug therapy*; D011468:Prostatectomy / Q000009:adverse effects; D013903:Thoracic Surgery; D013924:Thrombophlebitis / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D013997:Time Factors; D014628:Vagotomy / Q000009:adverse effects
D004087:Dihydroergotamine; D005340:Fibrinogen